BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
FDA updates risk classification for voluntary shredded cheese recall - 2Space debris: will it take a catastrophe for nations to take the issue seriously?
- 3Images of Bangladeshi motorcyclists sleeping at petrol pumps are AI-generated
- 4Evidence of lost baptismal rite stage uncovered in Byzantine era cathedral near Sea of Galilee
- 5Seoul says sorry after unapproved drone flights into North Korea
- Vietnam rethinks its flood strategy as climate change drives storms and devastation
- Green Inflections: A Manual for Inside Plants
- The 1 question we have to ask ourselves about the Taylor Frankie Paul 'Bachelorette' scandal
- Savvy Tips for Seniors Hyundai IONIQ EV
- 6 Fun Urban areas For Seniors To Travel
- Strengthening through Wellness: Individual Preparation Achievement
- Easter Island quarry reveals how Polynesians made enigmatic stone statues
- 10 Natural products to Remember for Your Eating routine for a Better You
- The next frontier in space is closer than you think – welcome to the world of very low Earth orbit satellites
